Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Siegal EZ. et al, (2025), NPJ vaccines, 10
Incidence of diabetes mellitus following hospitalisation for COVID‐19 in the United Kingdom: A prospective observational study
Tyrer F. et al, (2025), Diabetes, Obesity and Metabolism, 27, 767 - 776
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S. et al, (2025), EClinicalMedicine, 79
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.
De Voss CJ. et al, (2025), Frontiers in immunology, 16
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.
Korompis M. et al, (2025), Scientific reports, 15
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9
Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans
Voogd L. et al, (2024), Vaccines, 12, 1129 - 1129
Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
Taquet M. et al, (2024), The Lancet Psychiatry, 11, 696 - 708
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921
Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study - PHOSP-COVID.
Elneima O. et al, (2024), ERJ open research, 10, 982 - 2023
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Long COVID and cardiovascular disease: a prospective cohort study.
Lawson CA. et al, (2024), Open heart, 11
Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.
Balasingam S. et al, (2024), The Journal of infectious diseases
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Liew F. et al, (2024), Nature Immunology, 25, 607 - 621
Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.
Ma J. et al, (2024), Proceedings of the National Academy of Sciences of the United States of America, 121
Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study
Elneima O. et al, (2024), International Journal of Epidemiology, 53